Medpace Holdings Buy Recommendation

The 25-day quiet period on underwriter analyses that began with the August 11, 2016 IPO of Medpace Holdings (MEDP) will come to an end on September 5, allowing the firm’s many IPO underwriters to publish detailed positive reports and buy recommendations of the company on September 6. Our extensive research shows above-market returns during the period surrounding the company’s quiet period.

Medpace’s share price will likely see a temporary increase as a result of the release of underwriter reports. Since its IPO, Medpace Holdings has shown relatively strong performance. It opened at $27.79, higher than its IPO price of $23. Over the past month, the stock has bounced around, but reached a high on August 16 of $29.32 and a low of $27.13 on August 26. Currently, the shares trade around $28.

(Nasdaq.com)

Powerful Underwriters Could Boost Share Price at Quiet Period Expiration

We expect that Medpace’s IPO underwriters will seek to capitalize on the stock’s recent strong performance through the release of positive detailed reports beginning at the conclusion of the quiet period. These major underwriters include Credit Suisse Securities, Jefferies LLC, UBS Investment Bank, Wells Fargo Securities, and William Blair Inc.

Business Overview: Provider of Services to Biotechnology, Pharmaceutical, and Medical Device Industries

Medpace Holdings provides scientifically-driven, outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company offers a portfolio of services that support the clinical development process from Phase I to Phase IV along an array of therapeutic areas. Its services include quality assurance, core laboratory, biometrics, medical writing, global regulatory affairs, clinical monitoring, study start-up, study feasibility, clinical trial management, and medical affairs.

Medpace was founded by Dr. August Troendle in 1992 as a Phase II to Phase IV-focused contract research organization (CRO). The company maintains a strong, scientifically-driven business model, and Dr. Troendle retains a significant ownership stake in the company. Medpace focuses on conducting clinical trials across all therapeutic areas, including Endocrinology, Oncology, Metabolic Disease, Cardiology, Central Nervous System, Anti-Viral and Anti-Infective, and therapeutic expertise in medical devices. The company has approximately 2,300 employees in 35 countries in order to deliver broad access to diverse patient populations, market knowledge, and local regulatory expertise.